Related Experiment Video
Updated: Jul 2, 2026
Surgical Porcine Model of Chronic Myocardial Ischemia Treated by Exosome-laden Collagen Patch and Off-pump Coronary Artery Bypass Graft
Published on: September 15, 2023
A randomized comparative study of patients undergoing myocardial revascularization with or without cardiopulmonary
Whady Hueb1, Neuza H M Lopes, Bernard J Gersh
1Department Clinical Heart Institute of the University of Sao Paulo, Sao Paulo, Brazil. mass@incor.usp.br
Insights
The MASS III Trial compares on-pump versus off-pump heart surgery for multivessel coronary artery disease. It evaluates effectiveness, brain injury, quality of life, and cost-effectiveness for stable coronary artery disease patients.
Area of Science:
- Cardiovascular Surgery
- Interventional Cardiology
Background:
- The MASS III Trial is a single-institution study at The Heart Institute of the University of Sao Paulo, Brazil.
- It focuses on patients with coronary artery disease and preserved ventricular function.
Purpose of the Study:
- To compare the medical effectiveness, cerebral injury, quality of life, and cost-effectiveness of coronary surgery with and without cardiopulmonary bypass.
- To evaluate outcomes in patients with multivessel coronary artery disease undergoing either on-pump or off-pump surgery.
Main Methods:
- The primary endpoint is a composite of cardiovascular mortality, cerebrovascular accident, nonfatal myocardial infarction, and refractory angina requiring revascularization.
- Secondary endpoints include noncardiac mortality, angina, quality of life (SF-36), cost-effectiveness, exercise capacity, and neurocognitive evaluation.
- Cerebral injury is assessed using magnetic resonance imaging before and after procedures.
Main Results:
- This section is to be filled once the trial results are available.
Conclusions:
- This section is to be filled once the trial results are available.
Unlabelled:
The MASS III Trial is a large project from a single institution, The Heart Institute of the University of Sao Paulo, Brazil (InCor), enrolling patients with coronary artery disease and preserved ventricular function. The aim of the MASS III Trial is to compare medical effectiveness, cerebral injury, quality of life, and the cost-effectiveness of coronary surgery with and without of cardiopulmonary bypass in patients with multivessel coronary disease referred for both strategies. The primary endpoint should be a composite of cardiovascular mortality, cerebrovascular accident, nonfatal myocardial infarction, and refractory angina requiring revascularization. The secondary end points in this trial include noncardiac mortality, presence and severity of angina, quality of life based on the SF-36 Questionnaire, and cost-effectiveness at discharge and at 5-year follow-up. In this scenario, we will analyze the cost of the initial procedure, hospital length of stay, resource utilization, repeat hospitalization, and repeat revascularization events during the follow-up. Exercise capacity will be assessed at 6-months, 12-months, and the end of follow-up. A neurocognitive evaluation will be assessed in a subset of subjects using the Brain Resource Center computerized neurocognitive battery. Furthermore, magnetic resonance imaging will be made to detect any cerebral injury before and after procedures in patients who undergo coronary artery surgery with and without cardiopulmonary bypass.
Trials Registration:
Clinical Trial registration information ISRCTN59539154 Off-pump vs. on-pump surgery in patients with Stable CAD MASS III.
